KNTE

Kinnate Biopharma Inc. (KNTE) | Rumor.io

Kinnate Biopharma

KNTE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about KNTE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Mar 1

Kinnate Biopharma Inc. (KNTE) has sold its investigational Pan-RAF inhibitor, Exarafenib, to Pierre Fabre Laboratories for a total consideration of up to $31 million.
The sale includes a $30.5 million payment contingent upon the earlier of the dosing of the first patient in the first pivotal trial for Exarafenib or any other acquired asset, as well as $500,000 at closing.
The transaction yields approximately $0.75 per CVR (contingent value right) for shareholders, with the upper range for the transaction now having a decent possibility.

Generated by AI

Sentiment

Of the messages about KNTE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· Nov 15

Kinnate Biopharma Inc. ($KNTE) is up 28.03% in the pre-market, indicating a strong positive start to the trading day.
The company's shares have exploded on high relative volume, with a 29 RVOL, and are currently trading at $1.86, up 18% since the previous day's close.
The $2.50 call option for $KNTE has seen a 2,600% increase, suggesting a significant surge in investor interest and optimism for the company's stock.

Bearish· Nov 15

Kinnate Biopharma Inc. (KNTE) has laid off 90% of its staff, raising concerns about its ability to develop drugs.
KNTE's price action is seen as a pump and dump, with many expecting the stock to crash back under $2.00 by the end of the day.
The stock's recent surge is attributed to market makers manipulating the price, with some predicting a significant drop in the near future.

Generated by AI

Topics

Of the messages about KNTE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Mar 1

Kinnate Biopharma Inc. (KNTE) has entered into an asset purchase agreement with Pierre Fabre Laboratories for the global rights to exarafenib and other pan-RAF program assets.
The total consideration for the sale is up to $31 million, consisting of $500,000 at closing and a $30.5 million payment contingent upon the dosing of the first patient in the first pivotal trial for exarafenib.
The sale is expected to yield approximately $0.75 per CVR (capital stock) for shareholders, with the buyer also assuming up to $5 million in debt associated with the assets.

Technical Analysis· Nov 15

$KNTE is forming a bullish pennant, with a potential breakout above $2.67 and a target of $2.85 or $3.15.
The stock has shown multiple rejections within the $2.50 to $2.60 spread, and a break above $2.60 could act as a momentum indicator for a high break.
The stock's cup and handle pattern is developing, with a potential breakout above $2.50 and a target of $2.85 or $3.15.

Generated by AI

Community

Of the messages about KNTE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	58.33%
Newcomers	—	—	100%	41.67%

Regulars· Feb 16

Xoma has agreed to buy Kinnate Biopharma for $2.3352 to $2.5879 per share, plus a contingent value right, with the acquisition expected to close in April 2024.
The acquisition has sparked concern among regulars, who question how Kinnate Biopharma managed to burn through $60 million in six months despite restructuring and slashing costs.
Kinnate Biopharma's shares have been under significant pressure, falling over 67% in the past 12 months, and trading 309% above average volume with a 11.45% increase.

Newcomers· Nov 16

Newcomers are watching $KNTE for potential follow-through trades.
Investors are emphasizing the importance of taking small losses to avoid significant losses, citing a recent experience with $EBIX.
New traders are hoping for a fade in $KNTE after a breakout, aiming for a small win.

Generated by AI

Also Discussed

Investors talking about KNTE also mention

#	Name	Attention
1	Apollomics Inc.APLM	0%0
2	Naya Biosciences Inc.INVO	0%0
3	Solid Biosciences Inc.SLDB	0.3%new
4	Chemomab Therapeutics Ltd. American Depositary SharesCMMB	0%0
5	Cardio Diagnostics Holdings, Inc.CDIO	0%0
6	ALX Oncology Holdings Inc.ALXO	0%0
7	C4 Therapeutics IncCCCC	0%new
8	Sera Prognostics, Inc. Class A Common StockSERA	0%0
9	Vivos Therapeutics, Inc.VVOS	0%+0
10	Pliant Therapeutics Inc.PLRX	0%0